SCCA Breast Cancer Clinical Trials

This clinical trial will study medical charts and tumor samples from patients with male breast cancer treated within the past 20 years.

This is a multicenter study. Patients are stratified according to disease extent (metastatic vs non-metastatic).

Patient charts will be reviewed and data entered into a database. Data will be collected on patient epidemiology (e.g., age, ethnicity), possible risk factors (e.g., family history of cancer, chronic liver disease, obesity), and tumor characteristics (e.g., pathologic size, lymph node involvement, stage of disease, tumor grade, ER and PgR status, HER2 over-expression and results of BRCA 1 and 2 testing). Information regarding surgical therapy, radiotherapy, chemotherapy, and endocrine therapy will be collected. Patient outcomes, (e.g., disease recurrence or progression, new primary cancer, and overall survival) will be noted.

Tumor blocks must be collected and sent to central laboratories in United States (US samples) and in United Kingdom (Europe and the rest of the world samples) for central pathology assessment of several biomarkers in formalin-fixed, paraffin-embedded tissue. Fresh frozen tumor samples, when available, will be requested and analyzed in laboratories in Netherlands and US.

• Histologically confirmed invasive breast carcinoma diagnosed since 1990 to present date

  • Stage I-IV or recurrent disease (e.g., early, locally advanced, or metastatic disease)
• Concomitant ductal carcinoma in situ (CIS) or lobular CIS are allowed if invasive cancer is present
• Must have a formalin-fixed, paraffin-embedded tissue sample from primary tumor (e.g., biopsy or surgery)